Since I wrote last summer that Enzo Biochem (ENZ) made an attractive investment opportunity in light of recent M&A in the space, the stock is up 35%, respectable, but not what I had in mind.
(click to enlarge)
Since then, the company has reported four quarters of results. While the clinical lab business, which I called out as their most attractive asset, has performed alright, the products business has declined in every consecutive quarter.
Starting with the clinical lab, sales in 3 of the past 4 quarters have been encouraging. In the latest quarter reported, the company's results suffered from the effects of Hurricane Sandy, however, even excluding the hurricane, it appears revenues would have declined slightly...